NONOF News and Press, Novo-Nordisk A/S From 05/20/24

2024-05-20 08:20:00 ET Summary The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced positive results on its candidate, MariTide. Boeh...

2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...

2024-05-15 09:34:32 ET More on Danaher, Novo Nordis, etc. Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation ...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-14 14:42:53 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk: Patients on Wegovy maintain weight ...

2024-05-11 12:13:54 ET More on Fresenius Medical Care Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcr...

2024-05-10 10:16:35 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Dividend Roundup: Eli Lilly, A...

2024-05-02 12:21:14 ET Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 07:00 a.m. ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corpor...

2024-05-02 01:40:07 ET More on Novo Nordisk: Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo, Teva, AstraZeneca issued FTC war...

2024-05-01 17:07:44 ET Summary Amgen Inc. shares have dropped some 20% since reaching an all-time high in February due to a below-consensus outlook and patent concerns. The company's four pillars of growth are General Medicine, Oncology, Inflammatory Diseases, and Rare Diseases. ...